SHANGHAI JUNSHI BIO YC1
Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of malignant tumors, neurological, autoimmune, chronic metabolic, nervous system, and infectious diseases in the People's Republic of China. The company was founded in 2012 and is headquartered in Shanghai, People's Republic of … Read more
SHANGHAI JUNSHI BIO YC1 (8SJ) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, SHANGHAI JUNSHI BIO YC1 (8SJ) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
SHANGHAI JUNSHI BIO YC1 - Net Assets Trend (None–None)
This chart illustrates how SHANGHAI JUNSHI BIO YC1's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for SHANGHAI JUNSHI BIO YC1 (None–None)
The table below shows the annual net assets of SHANGHAI JUNSHI BIO YC1 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to SHANGHAI JUNSHI BIO YC1's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
SHANGHAI JUNSHI BIO YC1 Competitors by Market Cap
The table below lists competitors of SHANGHAI JUNSHI BIO YC1 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
PNB Housing Finance Limited
NSE:PNBHOUSING
|
$1.55 Billion |
|
AVIC (Chengdu) UAS Co. Ltd. A
SHG:688297
|
$1.55 Billion |
|
Pitney Bowes Inc
NYSE:PBI
|
$1.56 Billion |
|
Dynavax Technologies Corporation
NASDAQ:DVAX
|
$1.56 Billion |
|
Voltronic Power Technology Corp
TW:6409
|
$1.55 Billion |
|
Aboitiz Equity Ventures Inc
PINK:ABOIF
|
$1.55 Billion |
|
Ströer SE & Co. KGaA
PINK:SOTDF
|
$1.55 Billion |
|
Liveramp Holdings Inc
NYSE:RAMP
|
$1.55 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in SHANGHAI JUNSHI BIO YC1's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares SHANGHAI JUNSHI BIO YC1's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently SHANGHAI JUNSHI BIO YC1 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares SHANGHAI JUNSHI BIO YC1's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $338,657,802
- Average return on equity (ROE) among peers: -66.32%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| SHANGHAI JUNSHI BIO YC1 (8SJ) | €- | N/A | N/A | $1.55 Billion |
| 09R (09R) | $-2.13 Million | 0.00% | 0.00x | $10.61 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| Argen-X (1AE) | $4.10 Billion | -7.20% | 0.11x | $38.55 Billion |
| 1S90 (1S90) | $131.51 Million | -49.87% | 1.70x | $52.41 Million |
| Strategic Partners A/S (1TB0) | $19.25 Million | -1.55% | 0.22x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.50 Million |
| Intervacc AB (publ) (2E9) | $162.33 Million | -46.52% | 0.15x | $3.64 Million |
| 2F5 (2F5) | $-1.76 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $3.03 Million | -558.03% | 2.82x | $8.56 Million |